Trial Profile
A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Licarbazepine (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharma A.G.
- 15 Aug 2023 This trial has been discontinued in Czech republic.
- 28 Mar 2017 New trial record